Research

Brainstem clinical and neurophysiological involvement in COVID-19

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

The first 12 months of COVID-19: a timeline of immunological insights

The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome

Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19

Immunogenicity of the Ad26.COV2.S vaccine for COVID-19

Association of clinical, biological, and brain magnetic resonance imaging findings with electroencephalographic findings for patients with COVID-19